FA
ANIK icon

FDx Advisors’s Anika Therapeutics ANIK Stock Holding History

FDx Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,562
Closed -$388K – 631
2019
Q2 		$388K Sell
9,562
-366
-4% -$13.3K 0.02% 548
2019
Q1 		$300K Buy
+9,928
New +$340K 0.01% 600
2018
Q4 		– Sell
-11,221
Closed -$473K – 558
2018
Q3 		$473K Buy
11,221
+3,016
+37% +$119K 0.02% 538
2018
Q2 		$263K Buy
8,205
+1,253
+18% +$51.6K 0.01% 769
2018
Q1 		$346K Sell
6,952
-9
-0.1% -$508 0.01% 914
2017
Q4 		$375K Sell
6,961
-52
-0.7% -$2.88K 0.01% 920
2017
Q3 		$407K Buy
7,013
+1,401
+25% +$73.2K 0.01% 897
2017
Q2 		$277K Buy
5,612
+527
+10% +$24.3K 0.01% 1014
2017
Q1 		$221K Buy
+5,085
New +$243K 0.01% 1085

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

FDx Advisors's ANIK Position: Q3 2019 in Review

FDx Advisors sold out of Anika Therapeutics (ANIK) in Q3 2019, closing a stake of 9,562 shares — an estimated $388K sold.

FDx Advisors first reported a position in ANIK in Q1 2017 and held it in 9 quarters. The position peaked at $473K in Q3 2018. 194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

  • FDx Advisors reported no remaining Anika Therapeutics position as of Q3 2019 after selling out during the quarter.
  • FDx Advisors sold 9,562 Anika Therapeutics shares in Q3 2019, an estimated $388K.
  • FDx Advisors first reported a position in Anika Therapeutics in Q1 2017 and held it in 9 quarters.
  • FDx Advisors's Anika Therapeutics position peaked at $473K in Q3 2018.
  • 194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on FDx Advisors's 13F filing for Q3 2019, filed 7 Nov 2019.